Back to Market返回行情

EW Edwards Lifesciences Corporation

USHealthcare
$93.64-1.24%ClosedMarket Cap: $53.92B

As of 2026-07-08 16:00

Why EW matters now

Edwards Lifesciences Corporation (EW) is a US stock in Healthcare. The latest InvestLog snapshot shows $93.64 with -1.24% on the session and $53.92B in market capitalization; recent performance reads 1-month +6.33% and YTD +2.48%.

The latest financial table shown here is Q1 2026, with revenue of $1.65B, net income of $380.7M, and EPS of $0.66. Investors can compare that operating picture with valuation signals such as P/E 42.26 and FCF yield 2.2%.

The latest indexable market news headline is "Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $95.00; recent insider activity includes Zovighian Bernard J filing S-Sale; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

42.26

PEG

P/B

4.90

P/S

7.98

EV/EBITDA

34.18

DCF Value

$62.63

FCF Yield

2.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

78.0%

Operating Margin

27.6%

Net Margin

17.3%

ROE

10.6%

ROA

8.2%

ROIC

12.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$1.65B$380.7M$0.66
Q4 2025$1.57B$91.2M$0.16
FY 2025$6.07B$1.07B$1.83
Q3 2025$1.55B$291.1M$0.50

Analyst Ratings

Consensus

Buy

Target (Consensus)

$96.55

Target (Median)

$95.00

Target Range

$85.00 - $110.00

Strong Buy: 4Buy: 17Hold: 8Sell: 0Strong Sell: 0
RBC CapitalOutperform
2026-06-16
TD CowenBuy
2026-06-02
BarclaysOverweight
2026-04-27
BairdNeutral
2026-04-24
BTIGBuy
2026-04-24

Trading Activity

Insider Trades

Zovighian Bernard Jdirector, officer: CEO
Sell2026-06-17
Mistras Theodoraofficer
Sell2026-06-01
Dahl Andrew M.officer: SVP, Corporate Controller
Sell2026-05-29
BOBO DONALD E JRofficer: CVP,Strategy/Corp Development
Sell2026-05-27
Chopra Daveenofficer: CVP, TMTT & Surgical
Sell2026-05-22

Congress Trades

Ro KhannaBuy
2026-06-11

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.87

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.